RFHL Uppsala län

Fildena 150 mg contains sildenafil citrate as its active ingredient. Sildenafil citrate is a phosphodiesterase type 5 (PDE5) inhibitor. Its primary mechanism of action involves blocking the enzyme phosphodiesterase type 5, which is responsible for the breakdown of cyclic guanosine monophosphate (cGMP) in the smooth muscle cells of the penis.

When a man is sexually stimulated, Fildena 150 Mg oxide (NO) is released in the erectile tissue of the penis. Nitric oxide activates the enzyme guanylate cyclase, which leads to an increase in the production of cyclic guanosine monophosphate (cGMP). cGMP relaxes the smooth muscles in the penile arteries, allowing blood to flow into the penis, resulting in an erection.

Phosphodiesterase type 5 (PDE5) is responsible for breaking down cGMP, which terminates the erection by reversing the vasodilation. By inhibiting PDE5, sildenafil citrate prolongs the effects of cGMP, allowing the smooth muscles in the penis to remain relaxed for a longer duration. This sustained relaxation of the smooth muscles enhances blood flow into the penis, facilitating and maintaining an erection.

Therefore, Fildena 150 mg, like other sildenafil citrate medications, indirectly affects the production of cGMP by inhibiting the enzyme PDE5, which results in increased levels of cGMP in the penile tissues, promoting vasodilation and facilitating erectile function.